Miren Ruiz de Eguilaz
Miren Ruiz de Eguilaz, PhD, has an extensive academic background, earning a BSc in Biology from UPV/EHU, an MSc in Biotechnology from the University of Oviedo, and a PhD in Chemistry from Dublin City University (DCU).
Her doctoral research focused on developing electrochemical biosensors for bacteria detection as part of the Break Biofilms Training Network under the H2020-MSCA-ITN initiative. Miren’s expertise lies in biosensor technology and bacterial diagnostics.
She currently serves as a Product Manager at Assay Genie.
Connect with Miren or explore her work:
Recent Blogs by Miren:
Quick Facts About CobolimabWhat is Cobolimab?Cobolimab is a monoclonal antibody that targets TIM-3, a checkpoint protein involved in immune regulation, especially in cancer and autoimmune diseases.How does Cobolimab work?By inhibiting TIM-3, Cobolimab reactivates T-cells, boosting the immune system’s ability to identify and destroy [...]
Quick Facts About AtezolizumabWhat is Atezolizumab?Atezolizumab is an anti-PD-L1 monoclonal antibody used in immunotherapy to treat various cancers by enhancing the immune system's ability to attack tumors.What is the mechanism of action for Atezolizumab?Atezolizumab blocks the interaction between PD-L1 and PD-1, restoring T-cell [...]
Key Facts About EnoblituzumabWhat is Enoblituzumab?Enoblituzumab is a monoclonal antibody targeting the B7-H3 protein, which is expressed on the surface of various cancer cells, including those in prostate cancer, sarcoma, and ovarian cancer.What is the mechanism of action for Enoblituzumab?Enoblituzumab works by binding [...]
Publications by Miren:
Additional Resources
